Cognition and bioactive lipids in schizophrenia 306 Cognition, dopamine and bioactive lipids in schizophrenia

1. Abstract 2. Introduction 3. Cognition, neurotransmission, and membrane phospholipids in schizophrenia 3.1. Memory impairment in schizophrenia 3.1.1. Systems of memory 3.1.2. Memory deficits in schizophrenia patients 3.1.2.1. Verbal declarative memory 3.1.2.2. Semantic memory 3.1.3. Memory deficits in nonaffected family members of patients 3.2. Association between cognition and neurochemistry 3.2.1. Cognition and the dopamine hypothesis 3.2.2. Possible roles of polyunsaturated fatty acids (PUFAs) in cognition 3.2.2.1. n-3 PUFAs 3.2.2.1.1. Animal studies 3.2.2.1.2. Human studies 3.2.2.2. n-6 PUFAs 3.2.2.3. Eicosanoids (Arachidonic acid cascade) 3.3. Phospholipids signaling and schizophrenia 3.4. Interactions between monoaminergic neurotransmission and PUFAs: A model for neurocognitive deficits in schizophrenia 3.5. Hypothesis: The relationship between cognition and membrane phospholipids in schizophrenia is moderated by dopaminergic neurotransmission 3.5.1. Association between arachidonic acid and semantic memory, reading, and intelligence 3.5.1.1. Semantic memory 3.5.2. Association between semantic memory and dopamine turnover 3.5.3. Association between membrane phospholipids and dopamine turnover 4. Summary and perspective 5. Acknowledgements 6. References